Harpreet Singh, Chief Medical Officer at Precision For Medicine, shared on LinkedIn:
“In this CMO Confidential, I discuss a recent Journal of Clinical Oncology perspective from FDA authors on dose optimization for oncology radiopharmaceutical therapies.
The article highlights several questions the field is still working through, including how to define administered activity, how to think about acute versus cumulative toxicity, and how to move beyond traditional external beam radiation therapy organ tolerance frameworks.
For radiopharmaceutical therapies, dose optimization requires a careful balance between efficacy, short- and long-term safety, isotope- and target-specific considerations, and the clinical context in which the therapy is being developed.
Watch the full video below for more.
I’d like to credit these colleagues for advancing this important discussion: William Maguire, Donika Plyku, Sundeep Agrawal, Anthony Fotenos, Christy John, Haleh Saber, Stacy Shord, Alice Cheuk, August Hofling, Dan Suzman.”
Other articles about radiopharmaceutical therapies on OncoDaily.